| Suspended | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing He NCT06968195 | Roswell Park Cancer Institute | Phase 1 |
| Not Yet Recruiting | Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer NCT07042919 | Northwestern University | Phase 1 / Phase 2 |
| Recruiting | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Canc NCT07166406 | NRG Oncology | Phase 3 |
| Not Yet Recruiting | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tum NCT07405086 | OHSU Knight Cancer Institute | Phase 2 |
| Not Yet Recruiting | First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment NCT07297654 | National Cancer Center, Korea | Phase 2 |
| Recruiting | Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer NCT07174570 | Emory University | Phase 2 |
| Recruiting | Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combinatio NCT07227012 | Pfizer | Phase 1 / Phase 2 |
| Recruiting | Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) NCT06811116 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study of SZ1003 Injection in Patients With Advanced Hepatocellular Carcinoma NCT07201064 | Guangdong ProCapZoom Biosciences Co., Ltd. | EARLY_Phase 1 |
| Recruiting | A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma NCT06986785 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | Ligufalimab and Cadonilimab in Advanced Liver Cancers NCT06789848 | University of Texas Southwestern Medical Center | Phase 2 |
| Recruiting | Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma NCT06676982 | Zhejiang University | Phase 1 |
| Recruiting | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma NCT06600321 | Alnylam Pharmaceuticals | Phase 1 |
| Recruiting | Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for th NCT06618664 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 |
| Recruiting | A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients NCT06418659 | Shanghai Changzheng Hospital | EARLY_Phase 1 |
| Recruiting | Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma NCT06644430 | Sun Yat-sen University | — |
| Recruiting | dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma NCT06609863 | Sun Yat-sen University | N/A |
| Recruiting | Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma NCT06624098 | Sun Yat-sen University | N/A |
| Recruiting | Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma NCT06550921 | Sun Yat-sen University | N/A |
| Recruiting | Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma NCT06461624 | Zhejiang University | Phase 1 |
| Recruiting | Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma NCT06470256 | Zhiyong Huang | Phase 1 |
| Terminated | Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular NCT06320080 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Recruiting | Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma NCT06595108 | Yonsei University | N/A |
| Recruiting | Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment NCT06374485 | Lee's Pharmaceutical Limited | Phase 1 |
| Recruiting | Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma ( NCT05738616 | Wen Tianfu | Phase 3 |
| Recruiting | A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcin NCT06363825 | Fujian Medical University | Phase 2 |
| Recruiting | Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study NCT06301399 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Car NCT06326502 | Etnova Therapeutics Corp. | Phase 1 |
| Unknown | Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Tr NCT06244446 | Institute of Liver and Biliary Sciences, India | — |
| Unknown | A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients W NCT06233994 | Changsha Taihe Hospital | N/A |
| Completed | A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma NCT06092112 | Shanghai Changzheng Hospital | EARLY_Phase 1 |
| Recruiting | A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma NCT05797805 | Iterion Therapeutics | Phase 1 / Phase 2 |
| Unknown | To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307 NCT05783570 | Eutilex | Phase 1 |
| Recruiting | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer NCT05969860 | Mayo Clinic | Phase 2 |
| Terminated | A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules NCT05975645 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Unknown | A Clinical Study of mRNA Vaccine (ABOR2014/IPM511) in Patients With Advanced Hepatocellular Carcinoma NCT05981066 | Peking Union Medical College Hospital | N/A |
| Recruiting | Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcino NCT05924997 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 1 / Phase 2 |
| Active Not Recruiting | Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HC NCT05883644 | AstraZeneca | Phase 3 |
| Recruiting | Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients NCT06370065 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease NCT05791448 | University of Southern California | Phase 1 |
| Not Yet Recruiting | SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH) NCT05718232 | Sun Yat-sen University | Phase 3 |
| Unknown | A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC NCT05773105 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Recruiting | Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma NCT05620706 | Shenzhen University General Hospital | N/A |
| Recruiting | Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcin NCT05444088 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma NCT05290220 | Shanghai Henlius Biotech | Phase 2 |
| Terminated | GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma NCT05352542 | jianming xu | Phase 1 |
| Recruiting | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients NCT05213221 | Zhejiang University | Phase 2 |
| Recruiting | Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcin NCT05317819 | Polaris Group | Phase 3 |
| Completed | Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study NCT05117957 | Bo Hyun Kim | Phase 2 |
| Recruiting | Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcino NCT04430452 | Mary Feng, MD | Phase 2 |
| Completed | 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer NCT05176223 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells NCT05628545 | Guangdong GD Kongming Biotech LLC | Phase 1 / Phase 2 |
| Unknown | Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy NCT05620004 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Unknown | B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma NCT05070156 | Tongji University | EARLY_Phase 1 |
| Terminated | BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer NCT04777708 | Jonsson Comprehensive Cancer Center | EARLY_Phase 1 |
| Unknown | IMC001 for Clinical Research on Advanced Digestive System Malignancies NCT05028933 | Zhejiang University | Phase 1 |
| Recruiting | Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocell NCT05057845 | Fudan University | Phase 2 |
| Completed | A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Pati NCT04948697 | BeiGene | Phase 2 |
| Completed | Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liv NCT04828486 | Mayo Clinic | Phase 2 |
| Unknown | Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma NCT04973098 | Peking University | Phase 1 |
| Active Not Recruiting | Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepato NCT05097911 | National University Hospital, Singapore | Phase 1 |
| Unknown | Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevaci NCT05173298 | CHA University | — |
| Terminated | Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular Carcinoma NCT05845502 | Shantou University Medical College | N/A |
| Unknown | A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC NCT04331743 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Completed | Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC NCT04862949 | CHA University | — |
| Terminated | Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer NCT04442581 | University of Washington | Phase 2 |
| Completed | Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080 NCT04740307 | Merck Sharp & Dohme LLC | Phase 2 |
| Active Not Recruiting | Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma NCT04756648 | Zhejiang University | Phase 1 |
| Terminated | Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT NCT04709380 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 |
| Unknown | ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or NCT04730388 | University Hospital, Brest | — |
| Recruiting | Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma NCT06323382 | Sun Yat-sen University | — |
| Unknown | Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcino NCT04183088 | National Taiwan University Hospital | Phase 2 |
| Active Not Recruiting | Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection NCT04294498 | National Taiwan University Hospital | Phase 2 |
| Unknown | Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma NCT04503902 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma NCT04401813 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Unknown | Camrelizumab Utilization on Patients With Advanced Liver Cancer NCT04487704 | First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Completed | YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) NCT04000737 | Yiviva Inc. | Phase 2 |
| Completed | Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC NCT04611165 | National Cancer Center, Korea | Phase 2 |
| Unknown | To Explore the Diversity of Intestinal Flora in Patients With Advanced HCC Combin ed With Anti-PD-1 and Target NCT04101747 | Sun Yat-sen University | — |
| Terminated | Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC) NCT04066660 | Hi-Q Marine Biotech International, Ltd. | N/A |
| Completed | 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 NCT03980288 | Zhejiang University | Phase 1 |
| Unknown | TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma. NCT04417764 | Central South University | Phase 1 |
| Unknown | TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC NCT03905967 | Sun Yat-sen University | Phase 3 |
| Completed | Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma NCT03841201 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Unknown | Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcino NCT04052152 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Unknown | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Hav NCT03605706 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Unknown | A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma NCT03993743 | Xijing Hospital | Phase 1 |
| Unknown | Itacitinib in Advanced Hepatocellular Carcinoma NCT04358185 | Imperial College London | Phase 1 |
| Completed | Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinom NCT04072679 | Chinese Academy of Medical Sciences | Phase 1 |
| Withdrawn | Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT NCT05592197 | Sun Yat-sen University | N/A |
| Completed | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma NCT03586973 | Takeda | Phase 2 |
| Terminated | Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma NCT03059147 | SignalRX Pharmaceuticals, Inc. | Phase 1 |
| Completed | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With A NCT02834780 | H3 Biomedicine Inc. | Phase 1 |
| Withdrawn | Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma NCT01964235 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC NCT02795429 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma NCT02528643 | Astellas Pharma Global Development, Inc. | Phase 2 |
| Unknown | Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Trans NCT02638857 | Second Military Medical University | Phase 1 / Phase 2 |
| Unknown | Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced NCT02632006 | Second Military Medical University | Phase 1 / Phase 2 |
| Withdrawn | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma NCT02227914 | Amgen | Phase 1 / Phase 2 |
| Unknown | Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma NCT02150317 | Eastern Hepatobiliary Surgery Hospital | N/A |
| Completed | Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced NCT01897610 | GC Cell Corporation | Phase 2 |
| Terminated | A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and T NCT01942083 | Korea Otsuka Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Targeted Internal Radiation Therapy in Advanced HCC Patients. NCT02724267 | Eastern Hepatobiliary Surgery Hospital | N/A |
| Completed | Study of ARQ 197 in Hepatocellular Carcinoma (HCC) NCT01656265 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Terminated | Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanc NCT01539018 | Egyptian Society of Liver Cancer | Phase 2 |
| Completed | A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Can NCT01356628 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Unknown | Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma NCT01429961 | Seoul National University Hospital | Phase 2 |
| Unknown | Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC NCT01214343 | Ministry of Health, Labour and Welfare, Japan | Phase 3 |
| Completed | CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer NCT01033240 | Daiichi Sankyo | Phase 2 |
| Completed | A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma NCT01192971 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Completed | Siliphos in Advanced Hepatocellular Carcinoma NCT01129570 | Abby Siegel | Phase 1 |
| Completed | Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer P NCT00999882 | AstraZeneca | Phase 1 |
| Completed | A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellula NCT00872014 | Amgen | Phase 2 |
| Completed | XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) NCT00882869 | Aegera Therapeutics | Phase 1 / Phase 2 |
| Withdrawn | A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular C NCT00756782 | Taiho Oncology, Inc. | Phase 2 |
| Completed | Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC) NCT00731445 | Zeria Pharmaceutical | Phase 1 / Phase 2 |
| Terminated | Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Ja NCT00667628 | Taiho Oncology, Inc. | Phase 2 |
| Unknown | Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma NCT00752063 | The University of Hong Kong | Phase 2 |
| Completed | Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) NCT00517920 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma NCT00495846 | Federico II University | Phase 2 / Phase 3 |
| Completed | Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Car NCT00534664 | University of Sao Paulo | Phase 1 / Phase 2 |
| Completed | Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinom NCT00241020 | Novartis Pharmaceuticals | Phase 3 |